[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines
- Toni Ibrahim
- Chiara Liverani
- Laura Mercatali
- Emanuele Sacanna
- Michele Zanoni
- Francesco Fabbri
- Wainer Zoli
- Dino Amadori
- Published online on: July 6, 2016 https://doi.org/10.3892/ijo.2016.3613
- Pages: 1260-1260
Copyright: © Ibrahim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines
TONI IBRAHIM, CHIARA LIVERANI, LAURA MERCATALI, EMANUELE SACANNA, MICHELE ZANONI, FRANCESCO FABBRI, WAINER ZOLI and DINO AMADORI
[Related article:] Int J Oncol 42: 1263–1270, 2013; DOI: 10.3892/ijo.2013.1809
Following the publication of the above article, an interested reader drew an anomaly associated with the presentation of Fig. 7 to our attention. Essentially, the panel showing the Cis 0.001 data at T0 for the BRC-230 cell line was the same as that showing the Cis 0.01 data.
Effect of single and combined treatments on the migration ability detected by wound healing assay.
After having re-examined our data, we realized that an error must have occurred when preparing Fig. 7. A duplication of the photo corresponding to BRC-230 Cis 0.001 T0 was incorrectly placed in the position corresponding to BRC-230 Cis 0.01 T0, while the correct BRC-230 Cis 0.01 T0 figure was erroneously positioned in the BRC-230 Cis 0.01 T1 slot. Fortunately, we had retained all of the data on our computer and were able to find the correct photos representing the conditions of BRC-230 Cis 0.01 T0 and T1.
The correct version of Fig. 7 is shown below. The findings and conclusions of this paper are still supported by our experimental data and are not affected by this error. We sincerely apologize for this oversight and thank the reader for drawing this matter to our attention. We regret any inconvenience caused by our mistake.